Q2 2025 Management View Steven O. Vondran, President and CEO, stated that "2025 continues to be a good year." He highlighted ...

With a balanced risk/reward outlook and a 12-month price target of $277.95, we recommend holding as we monitor Lululemon's ...

Novo Nordisk's stock has dropped 21% after the company lowered its sales forecast and named Mike Doustdar as the new CEO.

The upgrade for emerging markets reflects a more optimistic outlook globally by the Fund, which nudged global GDP growth ...

Schneider adds that investors seem optimistic about American Tower due to stronger domestic organic growth heading into ...

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

The business has secured projects that include 400 kV quad transmission lines in India, 500/ 400/ 220 kV overhead transmission lines in the overseas market, and the supply of towers, hardware, and pol ...

Pharma giant Novo Nordisk A/S (NYSE:NVO) is plunging 21% to trade at a nearly three-year low of $54.27, after the company's ...

The merger and acquisition agreement being discussed between the parties, Tata Motors is likely to buy 27.1% from Exor. The ...

The IMF on Tuesday raised its global growth forecasts for 2025 and 2026 slightly, citing stronger-than-expected purchases ...

American Tower (AMT) stock dipped 2.3% in Tuesday premarket trading after REIT's 2025 AFFO guidance midpoint was ...

India is projected to grow at 6.4 per cent in fiscal year 2025 and 2026, and the country's stable growth is driven by a ...